Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


TGA chases PBAC on Trikafta

Posted 25 March 2021 PM

Vertex's triplet cystic fibrosis (CF) therapy Trikafta has been approved by the TGA in a decision announced close to two weeks after it was considered at the PBAC's March meeting.

CF is a genetic disorder caused by a defective and/or missing CFTR protein resulting from mutations in the CFTR gene, affecting approximately 3,500 people in Australia.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas